Molecular and Cellular Biology, April 2006, p. 2467-2478, Vol. 26, No. 7
0270-7306/06/$08.00+0 doi:10.1128/MCB.26.7.2467-2478.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Division of Hematology/Oncology and UC Davis Cancer Center, University of California at Davis, Davis, California,1 Molecular Biology Institute, Department of Pediatrics, and Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California2
Received 22 August 2005/ Returned for modification 1 October 2005/ Accepted 3 January 2006
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Among the potential biochemical mechanisms underlying promoter-specific DNA recognition by Ets proteins, two mechanisms are both important and related. First, most Ets proteins that have been examined show autoinhibition of DNA binding, such that the isolated Ets domains bind canonical DNA elements with an affinity that is substantially greater than that of the full-length protein (28). In many cases, this autoinhibition is subject to regulatory control in that it can be partially reversed by posttranslational modification (16, 29, 36). Second, many Ets proteins participate in cooperative DNA binding complexes with other transcription factors (8, 11, 14). The extended DNA sequences that support cooperative DNA binding include recognition sites for both the Ets protein and the relevant partner; thus, this mechanism serves both to increase the affinity for specific sites and to reduce the number of otherwise identical sites within the genome. These mechanisms have both been shown to operate for several members of the Ets family of transcription factors. In some cases, cooperative DNA binding has been shown to antagonize the autoinhibition intrinsic to Ets proteins, showing that these two mechanisms can participate to provide for enhanced specificity of DNA binding (12, 32).
Among the biologic activities of the Ets transcription factors, several different observations suggest that Ets proteins play a role in many different types of human cancer, including Ewing's sarcoma, a pediatric tumor of uncertain histologic origin (for a review, see reference 1). An important breakthrough in understanding the pathogenesis of Ewing's sarcoma was the identification of a specific chromosomal translocation, t(11;22), that is present in about 85% of cases. This translocation results in the expression of a novel EWS-Fli1 fusion protein in which the amino-terminal domain of EWS is fused to carboxyl-terminal sequences of Fli1, including the Fli1 Ets domain (6). Further work has demonstrated that essentially all cases of Ewing's sarcoma harbor a specific translocation in which the EWS gene is fused to one of five different genes (that for Fli1, ERG, Fev, ETV1/ER81, or ETV4/E1AF), all of which belong to the Ets family of transcription factors (1). The protein encoded by the EWS gene harbors RNA recognition motifs and is believed to function as an RNA binding protein. In the EWS-Ets fusion proteins that are characteristic of Ewing's sarcoma, the RNA recognition motif domains are not present.
It is generally believed that the EWS-Ets fusion proteins function as deregulated transcription factors in the pathogenesis of Ewing's sarcoma. This notion is supported by the facts that expression of EWS-Fli1 fusion proteins in mouse 3T3 fibroblasts results in cellular transformation and mutant EWS-Fli1 proteins that are impaired for DNA binding to consensus Ets binding sites show reduced transforming activity (23). As with other Ets proteins, the mechanisms by which the EWS-Ets fusion proteins found in Ewing's sarcoma regulate specific target promoters remain poorly understood. However, the gene for uridine phosphorylase (UPP) has been identified as a target gene whose expression is increased by direct binding of EWS-Fli1 to the promoter in 3T3 cells (7). Functional dissection of the UPP promoter identified a canonical Ets binding site at 130 bp relative to the transcription start site. Remarkably, this Ets site is immediately adjacent to an AP-1 site, and functional studies of the UPP promoter support the idea that the tandem Ets/AP-1 sites mediate UPP expression in response to Ras activation, as well as to EWS-Ets fusion proteins (7). Taken together, these data suggest a model in which EWS-Ets fusion proteins and AP-1 may cooperatively bind tandem promoter elements. Here we report the results of several different tests of this model, all of which support the idea that a subset of Ets proteins forms productive partnerships with Fos-Jun on DNA. Furthermore, our data support the hypothesis that such an interaction is critical to the ability of EWS-Ets fusions to target specific promoters and to induce cellular transformation.
| MATERIALS AND METHODS |
|---|
|
|
|---|
C were subcloned into the retroviral vector pBabepuro for expression in mammalian cells and into pFastBac for generation of recombinant baculovirus. PCR was used to clone the indicated fragments of Fli1, ERG, ETV1, Ets2, and PU.1 into plasmid pET15b. c-Fos and c-Jun expression plasmids were a kind gift of Greg Verdine (27). Antibodies used were Flag M2 monoclonal (Sigma), hemagglutinin (HA) monoclonal (Sigma), rabbit anti-Fli1 (C-19; Santa Cruz), rabbit anti-c-Fos (K25; Santa Cruz), and rabbit anti-c-Jun (H79; Santa Cruz). Protein expression and gel shift assays. EWS-Fli1 was expressed from recombinant baculovirus in insect cells and purified with Flag M2 agarose. 3T3 cell nuclear extract was prepared as previously described and was used as a source of full-length Fos-Jun in the experiments in Fig. 1. All other proteins were expressed in Escherichia coli as His6-tagged proteins and purified from the soluble fraction with nickel agarose. Ets proteins were Fli1 (amino acids 270 to 452), Fli1 (amino acids 270 to 371), ERG (amino acids 283 to 462), ETV1 (amino acids 324 to 477), Ets2 (amino acids 354 to 468), PU.1 (156 to 264), and Ets2-Fli1 (amino acids 354 to 444 of Ets2 fused in frame to amino acids 361 to 452 of Fli1). c-Fos (amino acids 118 to 211) and c-Jun (amino acids 247 to 340) proteins were purified as His6-tagged proteins from E. coli and were mixed to form Fos-Jun dimers before use in gel shift reactions.
|
Gel shift reaction mixtures contained binding buffer (10 mM Tris [pH 7.5], 2.5 mM KCl, 1 mM EDTA, 7% glycerol, 5 mM dithiothreitol, 0.05% NP-40, bovine serum albumin at 200 µg/ml, and nonspecific competitor DNA at 0.5 ng/µl) and either contained or did not contain 96 nM preformed Fos-Jun dimers in a 12-µl volume. Radiolabeled probes were prepared by a fill-in reaction with the Klenow fragment of DNA polymerase in the presence of 32P-labeled dATP. The reaction mixtures were incubated at room temperature for 20 min, followed by electrophoresis through 7% native polyacrylamide gels in 0.5x Tris-borate-EDTA. For the competition experiments shown in Fig. 1 and 2, a 200-fold excess of unlabeled competitor was added.
|
Cell culture and viruses. NIH 3T3 cells and Phoenix Eco cells were maintained in Dulbecco modified Eagle medium supplemented with 10% fetal calf serum, antibiotics, and 5% CO2. Transfections were performed with Lipofectamine, and retroviral infections were performed as previously described; selection was in puromycin-containing medium (1.5 µg/ml). Transfection for reporter gene assays used Lipofectamine with 200 ng of reporter gene, 300 ng of EWS-Fli1 expression plasmid, 100 ng of Renilla control plasmid, and 2.0 µg of carrier DNA per 6-cm dish. After transfection, cells were grown in medium containing 3% fetal calf serum to minimize ERK signaling. Forty hours after transfection, luciferase activity was determined with the Promega Dual Luciferase Reporter Assay System according to the manufacturer's specifications. The results are the average of at least three independent experiments performed in triplicate. Recombinant retroviruses directing the expression of the indicated proteins were generated as previously described (34).
RNA analysis and ChIP assays. RNA was isolated with Promega RNA Isolation Reagents according to the manufacturer's specifications, and Northern blot assays were performed as previously described (30). Chromatin immunoprecipitation (ChIP) experiments were carried out essentially as described by Louie et al. (21). Briefly, 108 cells were fixed with 1% formaldehyde for 10 min at room temperature. The cells were washed once in phosphate-buffered saline and scraped into 25 ml of phosphate-buffered saline. The cells were then washed once in buffer II (200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 10 mM HEPES, pH 6.5). The cell pellet was resuspended in 2.0 ml of lysis buffer (0.5% sodium dodecyl sulfate, 10 mM EDTA, 50 mM Tris, pH 8.1), and the cells were sonicated for 4 x 30 s with a Branson Sonifier set on 40% duty. The resulting material was centrifuged for 10 min at maximum speed in a refrigerated Eppendorf Microfuge, and the soluble material was diluted 10-fold in 0.5% Triton X-100-2 mM EDTA-150 mM NaCl-20 mM Tris, pH 8.1. A small aliquot of the starting material was analyzed by agarose gel electrophoresis, and the starting material was determined to be approximately 0.5 to 1.5 kb in size. The chromatin samples were incubated overnight with 60 µl of Flag M2 agarose before being washed extensively. The pellets were resuspended in TE plus 0.5% sodium dodecyl sulfate, and the cross-links were reversed by incubation at 65°C for 6 h. The recovered DNA was purified on QIAGEN PCR clean-up columns and eluted in 50 µl of water. Analysis was by both conventional PCR and SYBR Green reverse transcription-PCR; the UPP promoter primers have previously been described (7). The entire experiment was repeated three times with similar results each time.
| RESULTS |
|---|
|
|
|---|
The preferential formation of a higher-order complex on DNA suggested that EWS-Fli1 and Fos-Jun interact directly on DNA and raised the possibility that EWS-Fli1 and Fos-Jun may interact off of DNA. However, in coimmunoprecipitation experiments with cell extracts, we were unable to detect an interaction between EWS-Fli1 and Fos or Jun, suggesting that any interaction between EWS-Fli1 and Fos-Jun is confined to DNA (Fig. 2A and B). To search for interactions between Fos-Jun and EWS-Fli when bound to DNA, we performed experiments to define the relative dissociation rates of EWS-Fli1 in the presence and absence of Fos-Jun. The fraction of either ternary complex or EWS-Fli1-DNA complex remaining at different times after the addition of a large excess of unlabeled competitor was defined by gel shift experiments (Fig. 2D). The results showed that the half-off time for EWS-Fli1 in the absence of Fos-Jun (about 3 min) was considerably shorter than the half-off time in the presence of Fos-Jun (about 27 min), suggesting that the enhanced binding of EWS-Fli1 to DNA in the presence of Fos-Jun is due to increased stability of the ternary complexes. Note that EWS-Fli1 forms two complexes on the collagenase probe; this is due to the presence of a second, low-affinity site (Fig. 2C).
Truncated Fli1 and Fos-Jun proteins bind DNA cooperatively. Most models of EWS-Fli1 action propose that the EWS sequences provide a strong transcriptional activation domain but do not contribute to the DNA binding activity. The Fli1 sequences remaining in the oncogenic EWS-Fli1 fusion protein correspond to a short region upstream of the Ets domain, the Ets domain itself, and 90 amino acids C terminal to the Ets domain. We expressed this region, corresponding to amino acids 270 to 452 of Fli1, in bacteria and performed gel shift assays with this truncated version of Fli1 to look for cooperative DNA binding with a truncated Fos-Jun dimer that encodes the bZIP domain and a small amount of flanking sequence (Fig. 3). The results showed that the truncated version of Fli1, like EWS-Fli1, also formed a higher-order complex with Fos-Jun. Significantly, there was a strong preference for Fos-Jun-DNA over DNA alone in this experiment; the Fli1-Fos-Jun-DNA binding was half maximal at a Fli1 concentration of about 90 nM, while half-maximal binding in the Fli1-DNA complex was not achieved with a concentration of about 565 nM (Fig. 3A). The ternary complex showed a gradual decrease in migration with increasing amounts of Fli1 protein; this is likely due to nonspecific effects from the large change in the overall protein concentration as the amount of Fli1 protein is increased. As with full-length EWS-Fli1, the formation of a Fli1-Fos-Jun-DNA complex did not occur when the Ets site in the probe was mutated. While Fli1 protein in the absence of Fos-Jun bound poorly to the UPP site, much greater binding to the high-affinity Ets site from the Drosophila E74 gene was detected, with half-maximal binding of truncated Fli1 occurring at a concentration of 2 nM (data not shown). The results are consistent with previous site selection experiments, which demonstrated that the residues surrounding the 5'-GGAA-3' core sequence can substantially increase the affinity for monomeric binding by Fli1 (22).
|
We expanded this analysis to determine how different spacings between the Ets and AP-1 sites influenced the cooperativity by performing gel shift assays with a number of elements in which the spacing was varied from 1 to 22 bp. We observed similar levels of cooperativity in the binding of Fli1 (amino acids 270 to 452) to probes with the Ets and AP-1 sites separated by 1 nucleotide (UPP promoter), 6 nucleotides (a derivative of the human collagenase promoter), and 11 nucleotides (human collagenase) between the two sites (Fig. 4). In contrast, there was a decrease in the cooperative binding of Fli1 to probes with a spacing of 16 nucleotides (a derivative of human collagenase) and 22 nucleotides (mouse collagenase) such that half-maximal binding required about fourfold more protein. Inverting the orientation of the Ets binding site with regard to the AP-1 site in the human collagenase promoter supported cooperative binding at a level similar to that obtained with the wild-type promoter (data not shown). These results show that many different spatial arrangements, including alterations of both the spacing and the orientation of the Ets site, are compatible with cooperative DNA binding. They also suggest that there is a substantial decrease in cooperativity once the spacing reaches 16 bp.
|
|
|
|
C) or fusion of EWS sequences to the corresponding region of Ets2 resulted in loss of activation, while an EWS-Ets-Fli1 fusion protein retained the ability to activate reporter genes to a level similar to that of EWS-Fli1. The results demonstrate that the C-terminal 90 amino acids of Fli1 are essential for cooperative reporter gene activation with Fos-Jun.
The C terminus of EWS-Fli1 is required for biologic functions.
The finding that the C-terminal 90 amino acids of Fli1 are required for cooperative DNA binding provided a way to test the idea that the biologic activities of EWS-Fli1 are dependent on cooperative DNA binding. Toward this end, we expressed Flag-tagged EWS-Fli1 or EWS-Fli1
C in 3T3 cells from recombinant retroviruses. EWS-Fli1 and the
C mutant were expressed to similar levels, as measured by immunoblot assay of infected cells (Fig. 8A). As previously shown (7), expression of EWS-Fli1 led to a substantial increase in the amount of UPP mRNA detected by Northern blot assay, while the expression of UPP mRNA was only minimally increased in
C-expressing cells (Fig. 8B). To determine if EWS-Fli1 was directly bound to the UPP promoter, we performed ChIP experiments. Consistent with the Northern blot assays, we were able to detect recruitment of EWS-Fli1, but not
C, to the UPP promoter (Fig. 8B). To assess the role of the C terminus of EWS-Fli1 in cell transformation, we plated cells expressing EWS-Fli1 or
C in soft agar. EWS-Fli1-expressing cells formed colonies efficiently in soft agar, as previously shown (2). In contrast, the
C-expressing cells formed soft-agar colonies at a reduced level, although still above that of uninfected 3T3 cells (Fig. 8C). Taken together, these data show that the ability of EWS-Fli1 to cooperatively bind DNA with Fos-Jun is correlated with binding to the UPP promoter, UPP mRNA expression, and cell transformation.
|
| DISCUSSION |
|---|
|
|
|---|
Mutational analysis of the DNA sequences required for cooperative DNA binding shows that although the Ets binding site is absolutely required, there is a great deal of flexibility with regard to both the spacing and orientation of the Ets site. In addition, mutational analysis of the regions of Fli1 required for cooperativity indicate that, in addition to the Ets domain, the C terminus of Fli1 is required. Taken together, these data support a model of cooperativity in which the C terminus of Fli1 (or ERG or ETV1) makes direct physical contacts with the bZIP motif of Fos-Jun. Within the Ets family, this is most analogous to the interaction between Elk-1 and SRF. In that case, the Ets domain of Elk-1 contacts DNA directly, while the B box of Elk-1 makes direct physical contacts with SRF (14). Further analysis of the Fli1 C-terminal sequences should allow us to define the precise residues required for cooperativity.
It is clear from the biochemical analysis that prior DNA binding of Fos-Jun complexes can enhance the binding of EWS-Fli1 to DNA. Furthermore, our data indicate that this cooperativity is required for recruitment of EWS-Fli1 to the UPP promoter. Our data do not provide insight into the spectrum of EWS-Fli1 target genes that are controlled by DNA-dependent interactions between EWS-Fli1 and AP-1. While EWS-Fli1 may be recruited to different promoters by other interactions, the data are consistent with the idea that cooperative DNA binding is important for cell transformation. It may be possible to use RNA interference-mediated knockdown of Fos and Jun family proteins together with gene expression profiling to determine what fraction of EWS-Fli1-directed changes in gene expression are dependent on AP-1.
The evidence that tandem Ets and AP-1 sites direct gene expression, at least in part, through cooperative DNA binding may also be relevant in other biologic contexts. We and others have used different approaches to analyze gene expression induced during cell transformation by Fos and Jun proteins (10, 19, 25, 26, 35). These data support the idea that part of the transcriptional program induced by transforming Fos and Jun proteins may involve cooperation with Ets proteins. For example, the gene for HB-EGF has been shown be regulated during cell transformation by v-Jun, and the human collagenase gene is expressed at increased levels in Fos-transformed fibroblasts (10, 19). These data are consistent with the idea that oncogenic Fos and Jun may target some promoters by cooperative interactions with Ets proteins. Fos-Jun complexes have been shown to display cooperative DNA binding with at least two other transcription factors, NFAT and Oct-1, and the NFAT-AP-1-DNA complex has been analyzed by both biochemical and crystallographic methods (5, 27, 33). Both NFAT and Fli1 interact with the bZIP motif of Fos-Jun, suggesting that productive partnerships with several different partners can occur through this rather small domain.
Our data may also provide insights into the mechanisms of Ras- and Raf-induced gene expression. Many Ras- or Raf-induced genes harbor tandem Ets and AP-1 elements in their promoters. The Ets family member (or members) that might mediate Raf-dependent gene expression is not known, but the most attention has been focused on Ets2, as it is both ubiquitously expressed and a direct target of phosphorylation by ERK (36). Consistent with this, a dominant negative mutant form of Ets2, corresponding to the isolated Ets domain, was able to block Ras-dependent gene expression, as well as Ras-dependent cell transformation (9, 20). However, recent studies show that Ets2 knockout fibroblasts are susceptible to transformation by Ras (15). Furthermore, the dominant negative Ets2 allele blocks Ras-dependent gene expression in Ets2 knockout cells, implying that the dominant negative allele does not act only on Ets2. While the other targets of dominant negative Ets2 are not known, it is likely that they include other Ets family members. Therefore, the identities of the Ets proteins that cooperate with Fos-Jun downstream of Ras and Raf activation remain poorly defined. Our results suggest that members of either the Fli1 family (Fli1, ERG, and Fev) or the PEA3 family (ETV1, ERM, and E1AF/ETV4) are candidates for this function. Fli1, ERG, and Fev are expressed in a limited number of tissues, while ETV1, ERM, and E1AF are more generally expressed, suggesting that, in fibroblasts, these proteins may mediate Ras- and Raf-dependent gene expression. Importantly, ER81 has been shown to a target of ERK-dependent phosphorylation (4, 18). Further work is required to determine if ERK-dependent phosphorylation regulates cooperative DNA binding by these proteins and Fos-Jun in a manner analogous to the ERK-dependent regulation of Elk-1 DNA binding activity.
| ACKNOWLEDGMENTS |
|---|
This work was supported by NIH grant CA64118 to R.W.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Arvand, A., S. M. Welford, M. A. Teitell, and C. T. Denny. 2001. The COOH-terminal domain of FLI-1 is necessary for full tumorigenesis and transcriptional modulation by EWS/FLI-1. Cancer Res. 61:5311-5317.
3. Bartel, F. O., T. Higuchi, and D. D. Spyropoulos. 2000. Mouse models in the study of the Ets family of transcription factors. Oncogene 19:6443-6454.[CrossRef][Medline]
4. Bosc, D. G., B. S. Goueli, and R. Janknecht. 2001. Her2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene 20:6215-6224.[CrossRef][Medline]
5. Chen, L., J. N. Glover, P. G. Hogan, A. Rao, and S. C. Harrison. 1998. Structure of the DNA-binding domains from NFAT, Fos and Jun bound specifically to DNA. Nature 392:42-48.[CrossRef][Medline]
6. Delattre, O., J. Zucman, B. Ploufastel, C. Desmaze, T. Melot, M. Peter, H. Kovar, I. Joubert, P. de Jong, G. Rouleau, et al. 1992. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumors. Nature 359:162-165.[CrossRef][Medline]
7. Deneen, B., H. Hamidi, and C. T. Denny. 2003. Functional analysis of the EWS/ETS target gene uridine phosphorylase. Cancer Res. 63:4268-4274.
8. Escalante, C. R., A. L. Brass, J. M. Pongubala, E. Shatova, L. Shen, H. Singh, and A. Aggarwal. 2002. Crystal structure of PU.1/IRF-4/DNA ternary complex. Mol. Cell 10:1097-1105.[CrossRef][Medline]
9. Foos, G., J. J. Garcia-Ramirez, C. K. Galang, and C. A. Hauser. 1998. Elevated expression of Ets2 or distinct portions of Ets2 can reverse Ras-mediated cellular transformation. J. Biol. Chem. 273:18871-18880.
10. Fu, S., I. Bottoli, M. Goller, and P. K. Vogt. 1999. Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation. Proc. Natl. Acad. Sci. USA 96:5716-5721.
11. Garvie, C. W., J. Hagman, and C. Wolberger. 2001. Structural studies of Ets-1/Pax5 complex formation on DNA. Mol. Cell 8:1267-1276.[CrossRef][Medline]
12. Goetz, T. L., T.-L. Gu, N. A. Speck, and B. J. Graves. 2000. Auto-inhibition of Ets-1 is counteracted by DNA binding cooperativity with core-binding factor
2. Mol. Cell. Biol. 20:81-90.
13. Graves, B. J., and J. M. Petersen. 1998. Specificity within the ets family of transcription factors. Adv. Cancer Res. 75:1-55.[Medline]
14. Hassler, M., and T. J. Richmond. 2001. The B-box dominates SAP-1-SRF interactions in the structure of the ternary complex. EMBO J. 20:3018-3028.[CrossRef][Medline]
15. Hever, A., R. G. Oshima, and C. A. Hauser. 2003. Ets2 is not required for Ras or Neu/ErbB-2 mediated cellular transformation in vitro. Exp. Cell Res. 290:132-143.[CrossRef][Medline]
16. Hill, C. S., R. Marais, S. John, J. Wynne, S. Dalton, and R. Treisman. 1993. Functional analysis of a growth factor-responsive transcription factor complex. Cell 73:395-406.[CrossRef][Medline]
17. Hollenhorst, P. C., D. A. Jones, and B. J. Graves. 2004. Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res. 32:5693-5702.
18. Janknecht, R. 1996. Analysis of the ERK-stimulated transcription factor ER81. Mol. Cell. Biol. 16:1550-1556.[Abstract]
19. Johnson, I. M., H. J. Spence, J. N. Winnie, L. McGarry, J. K. Vass, L. Meagher, G. Stapleton, and B. W. Ozanne. 2000. Regulation of a multigenic expression programmed by the transcription factor, AP-1: re-expression of a down-regulated gene, TSC-36, inhibits invasion. Oncogene 19:5348-5358.[CrossRef][Medline]
20. Langer, S. J., D. M. Bortner, M. F. Roussel, C. J. Sherr, and M. C. Ostrowski. 1992. Mitogenic signaling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression. Mol. Cell. Biol. 12:5355-5362.
21. Louie, M. C., H. Q. Yang, A. H. Ma, W. Xu, J. X. Zou, H. J. Kung, and H. W. Chen. 2003. Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex. Proc. Natl. Acad. Sci. USA 100:2226-2230.
22. Mao, X., S. Miesfeldt, H. Yang, J. M. Leiden, and C. B. Thompson. 1994. The FLI-1 and chimeric EWS-FLI-1 oncoproteins display similar DNA binding specificities. J. Biol. Chem. 269:18216-18222.
23. May, W. A., M. L. Gishizky, S. L. Lessnick, L. B. Sunsford, B. C. Lewis, O. Delattre, J. Zucman, G. Thomas, and C. T. Denny. 1993. Ewing sarcoma 11:22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc. Natl. Acad. Sci. USA 90:5752-5756.
24. McCarthy, S. A., D. Chen, B. S. Yang, J. J. Garcia Ramirez, H. Cherwinski, X. R. Chen, M. Klagsbrun, C. A. Hauser, M. C. Ostrowski, and M. McMahon. 1997. Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1. Mol. Cell. Biol. 17:2401-2412.[Abstract]
25. McGarry, L. C., J. N. Winnie, and B. W. Ozanne. 2004. Invasion of v-Fos(FBR)-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes. Oncogene 23:5284-5292.[CrossRef][Medline]
26. Ordway, J. M., K. Williams, and T. Curran. 2004. Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1. Oncogene 23:3737-3748.[CrossRef][Medline]
27. Peterson, B. R., L. J. Sun, and G. L. Verdine. 1996. A critical arginine residue mediates cooperativity in the contact interface between transcription factors NFAT and AP-1. Proc. Natl. Acad. Sci. USA 94:13671-13676.
28. Pufall, M. A., and B. J. Graves. 2002. Autoinhibitory domains: modular effectors of cellular regulation. Annu. Rev. Cell Dev. Biol. 18:421-462.[CrossRef][Medline]
29. Pufall, M. A., G. M. Lee, M. L. Nelson, H. S. Kang, A. Velyvis, L. E. Kay, L. P. McIntosh, and B. J. Graves. 2005. Variable control of Ets-1 DNA binding by multiple phosphates in an unstructured region. Science 309:142-145.
30. Sprowles, A., and R. Wisdom. 2003. Oncogenic effect of delta deletion in v-Jun does not result from uncoupling Jun from JNK signaling. Oncogene 22:498-506.[CrossRef][Medline]
31. Thompson, A. D., M. A. Teitell, A. Arvand, and C. T. Denny. 1999. Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells. Oncogene 18:5506-5513.[CrossRef][Medline]
32. Treisman, R., R. Marais, and J. Wynne. 1992. Spatial flexibility in ternary complexes between SRF and its accessory proteins. EMBO J. 11:4631-4640.[Medline]
33. Ullman, K. S., J. P. Northrop, A. Admon, and G. R. Crabtree. 1993. Jun family members are controlled by a calcium-regulated, cyclosporin A-sensitive signaling pathway in activated T lymphocytes. Genes Dev. 7:188-196.
34. Wisdom, R., R. S. Johnson, and C. Moore. 1999. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 18:188-197.[CrossRef][Medline]
35. Wisdom, R., L. Huynh, D. Hsia, and S. Kim. 2005. Ras and TGF-b exert antagonistic effects on extracellular matrix gene expression and fibroblast transformation. Oncogene 24:7043-7054.[CrossRef][Medline]
36. Yang, B. S., C. A. Hauser, G. Henkel, M. S. Colman, C. van Beveren, K. J. Stacey, D. A. Hume, R. A. Maki, and M. C. Ostrowski. 1996. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol. Cell. Biol. 16:538-547.[Abstract]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|